In 2020, what challenges will pharmaceutical enterprises face in Q1 marketing?

[market analysis of pharmaceutical network] at the beginning of 2020, the change of drug market sales in the first quarter was unexpected At present, with novel coronavirus pneumonia outbreak and the promotion of prevention and control of epidemic situation, various industries have been affected more or less, especially for pharmaceutical companies So, in the first quarter of the epidemic, what will be the test for the marketing of pharmaceutical enterprises? First of all, from the current tense trend of the epidemic situation, it is predicted that academic conferences, salons, exhibitions, etc of all sizes in the first quarter will not be able to be held Taking this opportunity, representatives of marketing department and medicine can seize the time to consolidate their internal skills, focus outward and inward, and make a solid and deep understanding of product planning system and risk plan After all, all work needs to be done with a lot of accumulation rather than with a little taste Without a profound self-contained system and a logical academic system, the market sales force can only be achieved for a while without any aftereffect   In addition, in addition to the impact of the coming epidemic, with the strong promotion of national volume purchasing, the implementation of basic drug 1 + X policy, and the strong shuffle of local medical insurance and other policies, how to develop the pharmaceutical enterprises in a more professional direction, how to better integrate the business of the company, to promote the growth of new market terminals and the release of the stock market in 2020, is becoming a pharmaceutical enterprise Key issues for the next year's development At present, enterprises need to think about how to formulate reasonable strategies and suggestions in advance, instead of being beaten passively, which has been behind the policy In addition, it is expected that in the first quarter, the province's large-scale procurement will be basically suspended, and now all the concerns are on epidemic prevention and control But in the past, the large-scale purchase is still a big problem for pharmaceutical companies After all, from the perspective of procurement with volume in 2019, the dynamic adjustment of national basic drugs in 2020 has become a foregone conclusion It is also a basic task to accelerate the elimination of original supplementary varieties in provincial medical insurance catalogue According to the previous bidding procurement situation of each province, it is expected that the mode of large-scale national procurement will still be the trend of local procurement, and the exchange of price for quantity will also be the trend of this year In fact, in view of a series of reform measures, many people in the industry have said that the cold winter of the pharmaceutical industry has come Then, where should pharmaceutical companies go? In fact, every crisis itself contains both the root cause of failure and the seed of success In short, if handled properly, the crisis can turn into an opportunity As a large population country in the world, with the acceleration of the aging society, the scale of China's pharmaceutical health market will exceed 10 trillion in the future, and there is still a huge growth space Therefore, pharmaceutical enterprises should try to increase the channels and channels of product sales In this regard, some industry insiders said that pharmaceutical companies should first change the way they used to wait for customers to shop at home In order to maintain the balance between price marketing and production R & D investment, we need to improve the sharpness in word-of-mouth building, brand communication, etc.; brand building, building and communication need to be fully reflected in the whole closed loop of the enterprise In general, it is inevitable that the pharmaceutical pattern changes Pharmaceutical enterprises need to adjust the talent structure according to the market development trend and the enterprise's own needs The relative pharmaceutical sales mode also needs to make self planning and rapid change according to the enterprise's transformation When the whole industry is changing, the only way to remain unchanged is to wait and die.